• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-coated balloon developer Urotronic raises $6m

July 6, 2018 By Sarah Faulkner

UrotronicUrotronic has raised $6.1 million in an equity offering involving 21 investors, according to a document filed with the SEC this week.

The Minnesota-based company has not publicly stated how it plans to spend its newly-acquired funds. Urotronic is developing a drug-coated balloon catheter designed to treat urethral strictures in men.

Last month, Urotronic got the green light in Canada to begin treating people with urethral strictures using its Optilume device. Strictures, which can be caused by infections or trauma, block the path that urine takes to leave the body and can result in a slowing of the urinary system.

Urotronic’s device uses balloon dilation and an anti-proliferative drug to prevent blockages from recurring. In clinical trials, the Optilume device has succeeded in opening blockages and stopping the formation of scar tissue, according to Urotronic.

“We are quite excited to see this come to market,” Dr. Conrad Maciejewski, a reconstructive urologist at the Ottawa Hospital, said in prepared remarks.

“We are excited to introduce our innovative drug-coated balloon to the Canadian market and look forward to working with physicians and their patients who suffer from this debilitating disease,” Urotronic president & CEO, David Perry, added.

The company is making progress in the U.S., as well. In April, the FDA approved an investigational device exemption trial for Optilume. The 200-patient pivotal trial is slated to begin enrolling participants immediately.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Vascular Tagged With: urotronic

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS